Comprehensive analysis of relapsed‐refractory mature B‐cell non‐Hodgkin lymphoma in children and adolescents
The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).
Authors
- Verónica Celis (ORCID: https://orcid.org/0009-0007-9465-0424)
- Lorena Valero‐Arrese
- Ariadna Colmenero (ORCID: https://orcid.org/0000-0002-7966-0057)
- Jaime Verdú‐Amorós (ORCID: https://orcid.org/0000-0002-0900-0889)
- Leonie Frauenfeld (ORCID: https://orcid.org/0000-0003-4236-5799)
- Olga Balagué (ORCID: https://orcid.org/0000-0002-5099-3675)
- María Tallón
- Sara Mato (ORCID: https://orcid.org/0000-0001-7269-2470)
- Elı́as Campo (ORCID: https://orcid.org/0000-0001-9850-9793)
- Itziar Astigarraga (ORCID: https://orcid.org/0000-0002-5012-0137)
- Pilar Guerra‐García (ORCID: https://orcid.org/0000-0002-7740-0614)
- A. Galera (ORCID: https://orcid.org/0000-0002-5355-8003)
- Noelia Garcia
- Mara Andrés (ORCID: https://orcid.org/0000-0001-8274-5724)
- Itziar Salaverría (ORCID: https://orcid.org/0000-0002-2427-9822)
- Maitane Andión
- Natalia Castrejón de Anta (ORCID: https://orcid.org/0000-0002-0647-3058)
- Melina Pol (ORCID: https://orcid.org/0000-0002-4670-4252)
- Carmen Mendoza
- Lorenzo Carità
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- University of the Basque Country (ES)
- Hospital Universitario La Paz (ES)
- University Hospital Complex Of Vigo (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- BioCruces Health research Institute (ES)
- Complejo Hospitalario de Salamanca (ES)
- Hospital Infantil Universitario Niño Jesús (ES)
- Hospital Clínic de Barcelona (ES)
- Osakidetza (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- INCLIVA Health Research Institute (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1111/bjh.20012
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundación Científica Asociación Española Contra el Cáncer
- Deutsche Krebshilfe
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
- Departament de Salut, Generalitat de Catalunya